P0699 Comparative Effectiveness and Safety of Denosumab Versus Bisphosphonates in Osteoporosis Management Among Patients with Inflammatory Bowel Disease: A U.S. Propensity Matched Cohort Study

医学 德诺苏马布 炎症性肠病 比较有效性研究 骨质疏松症 内科学 倾向得分匹配 队列 疾病 肿瘤科 替代医学 病理
作者
Himsikhar Khataniar,Aakash Desai,Gursimran Kochhar
出处
期刊:Journal of Crohn's and Colitis [Oxford University Press]
卷期号:19 (Supplement_1): i1366-i1367
标识
DOI:10.1093/ecco-jcc/jjae190.0873
摘要

Abstract Background Denosumab, a fully monoclonal antibody, is approved for the treatment of osteoporosis, including glucocorticoid-induced osteoporosis. Denosumab is an alternative to bisphosphonate therapy and has been shown to improve bone mineral density, and reduce the incidence of new fractures, however there is limited data in patients with inflammatory bowel disease (IBD). Through this study we evaluate the effectiveness of denosumab versus bisphosphonates in reducing osteoporosis-related fractures and safety related to IBD-specific outcomes. Methods We conducted a retrospective cohort study using a U.S. multi-institutional database (TriNetX), examining patients with IBD with osteoporosis who were initiated on denosumab or bisphosphonates from 2013 to 2022. The primary aim of the study was to assess the 1- and 2-year risk of de-novo fractures (spine and/or hip) in the denosumab cohort compared to bisphosphonate cohort. Cox proportional hazard model was used to identify predictors of denosumab failure. The secondary aim was to evaluate the 2-year risk of IBD-related outcomes which included corticosteroid use, advanced therapy initiation, and surgery. 1:1 propensity score matching (PSM) was performed for demographics, comorbid conditions, BMI, hemoglobin, albumin, calcium/vitamin D supplementation, IBD medications including steroid use. Results Among 2,423 patients with IBD and osteoporosis (mean age 62.8, female sex 67.3%, Crohn’s disease 48.5%), 520 received denosumab and 1,903 received bisphosphonates. After PSM, there was no difference in the 1-year (2.33% vs 3.49%, aOR 0.65, 95% CI 0.31-1.38) and 2-year risk (4.65% vs 6.78%, aOR 0.65, 95% CI 0.39-1.14) of fractures between the denosumab cohort compared to the bisphosphonates cohort. In terms of IBD-related outcomes, denosumab was associated with a lower risk of prednisone use (aOR 0.73, 95% CI 0.56–0.96) but no significant difference in the risk of de-novo advanced therapy use (aOR: 0.76, 95% CI 0.442–1.334), IV steroid use (aOR 1.13, 95% CI 0.78–1.64) and surgery (aOR 0.79, 95% CI 0.49-1.27) [Table 1]. After cox regression analysis, chronic steroid use (HR 1.99, 95% CI 1.26-3.1), prednisone use (HR 1.71, 95% CI: 1.07–2.72) and history of falls (HR 3.00, 95% CI 1.34-4.09) as significant predictors of treatment failure with denosumab [Figure 1]. Conclusion Our study highlights the comparable effectiveness of denosumab compared to bisphosphonates in reducing the risk of fractures in patients with IBD and osteoporosis. There were no IBD-related safety signals related to denosumab use compared to bisphosphonates. Further prospective studies are needed to optimize osteoporosis management in this high-risk population.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SYX完成签到,获得积分10
刚刚
2秒前
梵高的向日葵完成签到,获得积分10
2秒前
Ava的应助被宇智波小小怪采纳,获得10
2秒前
sagitar的应助被哈哈采纳,获得20
2秒前
俏皮夏菡发布了新的文献求助20
2秒前
123564举报苹果的求助涉嫌违规
3秒前
3秒前
坚强孤容发布了新的文献求助10
4秒前
4秒前
yang666完成签到,获得积分10
4秒前
6秒前
7秒前
8秒前
灰白发布了新的文献求助30
9秒前
10秒前
欣喜雨真完成签到,获得积分10
12秒前
xixi完成签到,获得积分10
13秒前
高瑛键完成签到,获得积分10
13秒前
聪明的行云完成签到 ,获得积分10
13秒前
cy发布了新的文献求助10
14秒前
Hello的应助被mooncake187采纳,获得10
14秒前
15秒前
15秒前
16秒前
NexusExplorer的应助被标致的秋荷采纳,获得10
17秒前
明理冷梅完成签到 ,获得积分10
17秒前
灰白完成签到,获得积分10
17秒前
追光完成签到,获得积分10
18秒前
一兰完成签到 ,获得积分10
18秒前
Dryad完成签到,获得积分10
19秒前
20秒前
霡霂发布了新的文献求助10
20秒前
渡花发布了新的文献求助30
21秒前
Shawn完成签到,获得积分10
21秒前
21秒前
冷傲路灯完成签到 ,获得积分10
23秒前
极HAO完成签到,获得积分10
23秒前
小情绪发布了新的文献求助10
24秒前
山外方有山完成签到,获得积分10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186750
求助须知:如何正确求助?哪些是违规求助? 9575027
关于积分的说明 21839240
捐赠科研通 7784331
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559206
邀请新用户注册赠送积分活动 2481611